Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Fineline Cube Apr 1, 2026
Company Drug

Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone

Fineline Cube Jan 11, 2023

US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor...

Company Deals

HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges

Fineline Cube Jan 11, 2023

The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022,...

Company Drug

Konruns Initiates Phase II Study for KC1036 in Advanced Thymic Tumors

Fineline Cube Jan 11, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the initiation of a single-arm, open,...

Company Drug

Dizal’s Sunvozertinib NDA Accepted for Review by China’s NMPA

Fineline Cube Jan 11, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...

Company Drug

HighTide Therapeutics Doses First Patient in Phase IIb Study for HTD1801 in NASH

Fineline Cube Jan 11, 2023

Shenzhen-based HighTide Therapeutics Inc. has announced that the first patient has been dosed in a...

Drug

MSD Submits Initial Quotation for Molnupiravir in China Amid New COVID-19 Rules

Fineline Cube Jan 11, 2023

Under new rules specifically for the launch of COVID-19 therapeutics in China, US-based Merck Sharp...

Company Drug

Treadwell Therapeutics’ CFI-402257 Granted Fast-Track Status by FDA

Fineline Cube Jan 11, 2023

China-based clinical-stage biotech Treadwell Therapeutics has announced receiving fast-track status from the US Food and...

Policy / Regulatory

CDE Releases 66th Batch of Chemical Generic Reference Preparations

Fineline Cube Jan 11, 2023

The Center for Drug Evaluation (CDE) has released the 66th batch of chemical generic reference...

Company Drug

Jiangsu Kanion’s KYS202002A Greenlit for Clinical Study in Multiple Myeloma

Fineline Cube Jan 11, 2023

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving approval from the National...

Company Deals

Gaoling Medical Secures Funding for Infrared Thermotherapy Technology

Fineline Cube Jan 11, 2023

Gaoling Medical, a Hangzhou-based developer of systemic infrared thermotherapy technology, has raised an undisclosed amount...

Company Drug

Yiling Pharmaceutical’s BIO-008 Accepted for Review by China’s NMPA

Fineline Cube Jan 11, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...

Company Deals

Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China

Fineline Cube Jan 11, 2023

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has...

Company Deals

CanSino Biologics to Issue GDRs on SWX Swiss Exchange to Boost Globalization

Fineline Cube Jan 11, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced plans to issue an undisclosed amount...

Company Drug

Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong

Fineline Cube Jan 11, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program...

Company Drug

Innovent Biologics Doses First Patient in Phase III Study for Mazdutide

Fineline Cube Jan 10, 2023

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...

Policy / Regulatory

China Meheco Keyi Pharma’s Ganciclovir Loses VBP Bid After Inspection Failure

Fineline Cube Jan 10, 2023

The national drug alliance procurement office has released a notification indicating that China Meheco Keyi...

Policy / Regulatory

NMPA Releases 63rd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has released the 63rd batch of reference drugs for...

Company Drug

Cosunter’s COVID-19 Drug GST-HG171 Shows Superior Efficacy in Trial

Fineline Cube Jan 10, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced positive results from an investigator-initiated...

Company Drug

Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China

Fineline Cube Jan 10, 2023

The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...

Policy / Regulatory

NMPA Approves Expanded Production for COVID-19 Symptom Treatments

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has approved filings from multiple companies to expand manufacturing...

Posts pagination

1 … 554 555 556 … 645

Recent updates

  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
  • Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
  • Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
  • Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Company Drug

Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.